Evaluation of maternal serum SERPINC1, E-selectin, P-selectin, RBP4 and PP13 levels in pregnancies complicated with preeclampsia

Abstract

Objective

The aim of this study is to investigate whether Serpin clade C (SERPINC1), E-selectin, P-selectin, Placental protein 13 (PP13), and Retinol-binding protein-4 (RBP4) levels in maternal serum were associated with the presence of preeclampsia and to compare them with uncomplicated pregnancies.

Methods

This prospective study included 40 women with preeclampsia and 40 healthy pregnant women. An enzyme-linked immunosorbent assay kit was used to measure serum SERPINC1, E-selectin, P-selectin, PP13, and RBP4 levels.

Results

The preeclampsia group had significantly higher E-selectin and P-selectin levels than the control group. PP13 and SERPINC1 levels were also significantly lower than the control group. There was no significant difference in RBP4 levels. The receiver operating characteristic curve revealed the best cutoff values for the following: E-selectin >19.2 ng/mL, with 87.5% sensitivity and 95% specificity; P-selectin >5.1 ng/mL, with 97.5% sensitivity and 100% specificity; PP13 ≤ 107.03 pg/mL, with 72.5% sensitivity and 77.5% specificity; and SERPINC1 ≤ 87.76 ng/mL, with 100% sensitivity and 97.5% specificity.

Conclusion

In this study, the endothelial dysfunction parameters SERPINC1, PP13, E-selectin, and P-selectin were found to be associated with preeclampsia. Endothelial dysfunction biomarkers in maternal non-serum body fluids may differ. More research is needed, especially to determine the relationship between SERPINC1 and preeclampsia.

Keywords:

• Endothelial dysfunction
• E-selectin
• PP13
• preeclampsia
• P-selectin
• RBP4
• SERPINC1
• third trimester

Acknowledgments

Ethics approval and consent to participate: The Ethics Committee approved the study protocol (Date: February 19, 2020; approval number: B.10.1.TKH.4.34.H.GP.0.01/28). Written informed consent was obtained from all individual participants included in the study.

Authors’ contributions

Both authors contributed to the study’s conception and design. Material preparation and data collection and analysis were performed by RM Palalioglu and HI Erbiyik. The first draft of the manuscript was written by RM Palalioglu. commented on previous versions of the manuscript. All authors read and approved the final manuscript. Conceptualization: RM Palalioglu; Methodology: RM Palalioglu; Formal analysis and investigation: RM Palalioglu and HI Erbiyik; Writing – original draft preparation: RM. Palalioglu, HI Erbiyik; Writing – review and editing: RM Palalioglu and HI Erbiyik; Resources: RM Palalioglu and HI Erbiyik; Supervision: RM Palalioglu and HI Erbiyik.

Consent for publication

Patients signed informed consent regarding publishing their data.

Disclosure statement

The authors declare that they have no conflict of interest.

Availability of data and material

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.